Cellcor & Organon Technika/Biotech Research Institute
Executive Summary
Jointly sponsored Phase I clinical trial of the companies' cellular therapy technologies will involve approximately 15 patients with stage IV metastatic renal cell carcinoma who will receive OT/BRI's active specific immunotherapy followed by Cellcor's autolymphocyte therapy. The trial is the first time two cellular therapies have been used together, Cellcor says. The companies believe the synergy of specific and non-specific immune system activation will result in "reduced tumor size and growth rate and prolonged quality survival." The trial will take place at Georgetown's Lombari Cancer Center